Tea for preventing and treating non-alcoholic fatty liver disease and preparation method thereof

Abstract

The present invention provides a tea drink for preventing and treating non-alcoholic fatty liver disease, comprising the following ingredients by weight: 2-4 parts of cassia seed, 2-4 parts of mulberry leaf, 1-2 parts of gynostemma pentaphyllum, 1-2 parts of hawthorn, 0.5-1.5 parts of dried orange peel, 0.5-1 parts of atractylodes macrocephala, 0.5-1 parts of tuckahoe, 1-2 parts of astragalus, and 1-2 parts of aged fu brick tea. The tea drink for preventing and treating non-alcoholic fatty liver disease of the present invention can reduce the accumulation of fatty substances in the liver, thereby having a good effect of preventing non-alcoholic fatty liver disease. The present invention also provides a preparation method of a tea drink for preventing and treating non-alcoholic fatty liver disease.

Description

Technical Field

[0001] The invention relates to the technical field of traditional Chinese medicines, and in particular to a tea drink for preventing and treating non-alcoholic fatty liver disease and a preparation method thereof. Background Art

[0002] Nonalcoholic fatty liver disease (NAFLD) refers to a clinical pathological syndrome characterized by diffuse hepatocyte macrovesicular fat change, with liver fat accumulation exceeding 5% of liver weight, excluding alcohol and other clear liver damage factors (including infectious hepatitis, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, hemochromatosis, α1-antitrypsin deficiency, Wilson's disease, and drug-induced hepatitis). Common manifestations of patients include indigestion, swelling and pain in the liver area, etc. If effective treatment is not taken in time, the disease will progress recklessly, and in addition to causing liver-related diseases, adverse complications such as cardiovascular and chronic kidney diseases should not be ignored.

[0003] With the improvement of people's living standards, changes in dietary structure and lifestyle, the incidence of NAFLD is about 20-30% in the general population, and as high as 75% in obese people, which has caused a huge burden on patients' health and society. At present, there is no effective drug for this disease in clinical practice. The commonly used method is mainly to change the lifestyle, and appropriately cooperate with lipid-lowering, antioxidant drugs and insulin sensitizers. However, long-term medication not only increases the economic burden of patients, but also causes a great burden on the liver and kidneys of patients, making patients' clinical compliance poor, and the disease gradually worsens over time.

[0004] For this reason, it is urgent to find a safe and effective food drug that can effectively curb its further development. Tea is one of the most popular beverages in the world, especially in Eastern countries such as China, Japan and Singapore. The consumption of tea beverages has been considered the second largest in the world (the first is water). Long-term tea drinking may be beneficial to human health, for example, reducing the risk of chronic diseases, including cancer, diabetes, cardiovascular disease, neurological disease and liver disease.

[0005] In view of this, the object of the present invention is to provide a tea drink for preventing and treating non-alcoholic fatty liver disease. Summary of the invention

[0006] The technical problem to be solved by the present invention is to provide a tea drink for preventing and treating non-alcoholic fatty liver disease, which can reduce the accumulation of fatty substances in the liver and thus has a better effect of preventing non-alcoholic fatty liver disease.

[0007] The technical solution of the present invention is as follows:

[0008] A tea for preventing and treating non-alcoholic fatty liver disease, characterized in that it comprises the following ingredients by weight: 2-4 parts of cassia seeds, 2-4 parts of mulberry leaves, 1-2 parts of gynostemma pentaphyllum, 1-2 parts of hawthorn, 0.5-1.5 parts of tangerine peel, 0.5-1 part of atractylodes macrocephala, 0.5-1 part of poria, 1-2 parts of astragalus, and 1-2 parts of aged fu brick tea.

[0009] Preferably, a tea for preventing and treating non-alcoholic fatty liver disease comprises the following ingredients by weight: 2.5 parts of cassia seeds, 2.5 parts of mulberry leaves, 1.5 parts of gynostemma pentaphyllum, 1.5 parts of hawthorn, 1.0 part of tangerine peel, 0.5 part of atractylodes macrocephala, 0.5 part of poria, 1 part of astragalus, and 1 part of aged fu brick tea.

[0010] Furthermore, the aged Fuzhuan tea is prepared by the following preparation process:

[0011] Select high-quality dark tea, steam it for 5-7 minutes, pour it into a wooden warehouse, lay it flat at a height of 1-1.2m, ferment it for 12-15 hours, and ferment it at a temperature of 40-60°C; wherein the steaming time can be 5 minutes, 6 minutes or 7 minutes, or other values ​​within the range; the fermentation time can be 12 hours, 13 hours / 14 hours or 15 hours, or other values ​​within the range; the fermentation temperature can be 40°C, 45°C, 50°C, 55°C or 60°C, or other values ​​within the range;

[0012] The tea is naturally blossomed at 24-26°C (such as 24°C, 25°C or 26°C, or other values ​​within the range) and relative humidity of 65-75% (the humidity condition can be 65%, 68%, 70%, 72% or 75%, or other values ​​within the range). When white mycelium appears in the brick tea, the temperature is raised to 27.5-28.5°C (such as 27.5°C, 28°C or 28.5°C, or other values ​​within the range), and the humidity is 75% to 85% (such as 75%, 80% or 85%, or other values ​​within the range); when luxuriant Eurotium cristatum is seen growing in the brick tea, the humidity is controlled at 55-65% (such as 55%, 60% or 65%, or other values ​​within the range) until the blossom is completed;

[0013] After the flowering is completed, the temperature is raised by 3-4°C (such as 3°C, 3.5°C or 4°C, or other values ​​within the range) every day until the temperature reaches 50°C and kept warm for 2 days, then the temperature is lowered to 35°C at a rate of 2°C / day; then the temperature is raised to 40°C at a rate of 1°C / day until the brick tea is dry, and the finished tea leaves are produced;

[0014] The finished tea leaves are fermented and aged in an environment with moderate temperature and humidity, good ventilation, freshness and no odor.

[0015] The present invention also provides a method for preparing a tea drink for preventing and treating non-alcoholic fatty liver disease, comprising the following steps:

[0016] Step S1, removing impurities from each raw material, weighing and washing;

[0017] Step S2, performing a primary drying treatment on the washed raw materials;

[0018] Specifically, the washed raw materials are filtered through a water filtering device, and the separated raw materials are air-dried at a temperature of 60-80°C; the drying temperature may be 60°C, 65°C, 70°C, 75°C or 80°C, or other values ​​within the range.

[0019] Step S3, crushing the raw material after the primary drying, and the particle size of the particles after crushing is 150-200 mesh;

[0020] Step S4, putting the crushed raw materials into a mixer and stirring them evenly;

[0021] Step S5, secondary drying of the mixed raw materials;

[0022] Step S6, sterilizing the raw materials after secondary drying;

[0023] Step S7, packing the sterilized raw materials into filter bag papers and sealing them.

[0024] Furthermore, the step S3 specifically includes:

[0025] Step S31, putting the raw material after the primary drying into a pulverizer for primary pulverization;

[0026] Step S32, using a screening device to screen the raw material after the primary crushing, wherein the screening device is a flat circular screen;

[0027] Step S33, secondary crushing of the screened large-particle raw materials.

[0028] Further, in step S5, the raw material is placed in a vacuum drying oven for drying, the vacuum degree is 0.01-0.1Mpa, and the drying temperature is 60-80°C. The vacuum degree can be 0.01Mpa, 0.02Mpa, 0.05Mpa, 0.08Mpa or 0.1Mpa, or other values ​​within the range; the drying temperature can be 60°C, 65°C, 70°C, 75°C or 80°C, or other values ​​within the range.

[0029] Furthermore, in step S6, the raw materials are sterilized by ultraviolet light.

[0030] Compared with the prior art, the tea beverage for preventing and treating non-alcoholic fatty liver disease and the preparation method thereof provided by the present invention have the following beneficial effects:

[0031] 1. The tea drink for preventing and treating non-alcoholic fatty liver provided by the present invention is to protect and nourish the liver, invigorate qi and strengthen the spleen as the foundation, and to remove phlegm and blood stasis and detoxify as the temporary treatment. According to the theory of traditional Chinese medicine, the traditional compatibility theory and the modern medical theory, the cassia seed in the prescription is bitter, sweet and salty, slightly cold in nature, clears the liver and improves eyesight; the mulberry leaf is sweet and bitter, cold in nature, clears the liver and improves eyesight, and the two are the main medicine. Gynostemma pentaphyllum is cold in nature, bitter in taste, removes phlegm and removes turbidity; hawthorn is sour and sweet in taste, warm in nature, helps digestion and strengthens the stomach, promotes qi and disperses blood stasis, and the two are the ministerial medicine. Tangerine peel is bitter and pungent in taste, warm in nature, regulates qi and strengthens the spleen, dries dampness and resolves phlegm; Astragalus is sweet in taste, slightly warm in nature, tonifies qi and raises yang, and strengthens qi and consolidates the exterior; Atractylodes macrocephala is bitter and sweet in taste, warm in nature, and is sweet and light in nature, flat in nature, dries dampness and strengthens the spleen when combined with Poria cocos, and the four are adjuvant medicines. Tea is cool in nature, clears the head and eyes, helps digestion and reduces fat, promotes urination, detoxifies, eliminates thirst, and harmonizes various medicines, and is an adjuvant medicine. The nine ingredients are shared to clear and nourish the liver, remove turbidity and reduce fat, activate blood circulation and remove blood stasis, invigorate qi, strengthen the spleen and remove phlegm, and assist in reducing blood lipids. The tea drink for preventing and treating non-alcoholic fatty liver of the present invention can significantly improve the pathological changes of fatty liver. Its mechanism of action is to improve fatty liver by reducing lipid deposition in the liver and alleviating peroxidation damage to prevent and treat fatty liver; and it can resist inflammation and fibrosis to prevent non-alcoholic fatty liver from further developing into non-alcoholic fatty hepatitis and liver fibrosis.

[0032] 2. The tea for preventing and treating non-alcoholic fatty liver disease provided by the present invention can effectively treat non-alcoholic fatty liver disease, especially can improve its insulin resistance, and can also reduce the levels of alanine aminotransferase, aspartate aminotransferase, triglycerides, total cholesterol, low-density lipoprotein, high-density lipoprotein, waist circumference, weight and body mass index.

[0033] 3. The tea beverage for preventing and treating non-alcoholic fatty liver disease provided by the present invention has simple ingredients and multiple functions. While having the functions of reducing liver fat accumulation, protecting liver cells, and preventing non-alcoholic fatty liver disease, it also has the functions of anti-oxidation, lowering blood lipids, losing weight, regulating intestinal flora, anti-virus, and anti-cancer.

[0034] 4. The tea for preventing and treating non-alcoholic fatty liver disease provided by the present invention comprises Chinese medicinal materials that are both edible and medicinal, without any chemical additives, and will not increase the burden on the liver and kidneys and will not produce toxic side effects on the body.

[0035] 5. The tea beverage for preventing and treating non-alcoholic fatty liver disease provided by the present invention is in powder form, and the lipid-lowering active ingredients are more easily precipitated during the extraction process, thereby improving the utilization rate of the lipid-lowering and liver-protecting active ingredients. DETAILED DESCRIPTION

[0036] In order to enable those skilled in the art to better understand the technical solutions in the embodiments of the present invention and to make the above-mentioned objects, features and advantages of the present invention more obvious and understandable, the specific implementation modes of the present invention are further described below.

[0037] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0038] The tea for preventing and treating nonalcoholic fatty liver disease of the present invention comprises the following ingredients by weight: 2-4 parts of cassia seeds, 2-4 parts of mulberry leaves, 1-2 parts of gynostemma pentaphyllum, 1-2 parts of hawthorn, 0.5-1.5 parts of tangerine peel, 0.5-1 part of atractylodes macrocephala, 0.5-1 part of poria, 1-2 parts of astragalus, and 1-2 parts of aged fu brick tea.

[0039] The properties, flavors, meridians and effects of each ingredient in this formula are as follows:

[0040] Gynostemma pentaphyllum

[0041] [Nature and flavor and meridians entered] Cold in nature, bitter in taste. Enters the lung, stomach and heart meridians.

[0042] [Ingredients] Contains gypenosides-52, of which 3, 4, 8, and 12 have the same structure as ginsenosides (Rb1, Rb3, Rb, Rf2), and also contains flavonoids and sugars.

[0043]

Effects

[0044] Tangerine peel

[0045]

Nature and flavor and meridians

[0046]

Ingredients

[0047] [Effects] Regulates Qi and strengthens the spleen, dries dampness and resolves phlegm. Used for chest and abdominal distension, loss of appetite, vomiting and diarrhea, cough and phlegm. Nobiletin is one of the effective ingredients of tangerine peel. It is a polymethoxylated flavonoid compound with pharmacological effects such as inhibiting inflammatory response, removing dampness and resolving phlegm, promoting blood circulation and removing blood stasis, anti-tumor, and improving non-alcoholic fatty liver.

[0048] hawthorn

[0049]

Nature and flavor and meridians

[0050] [Ingredients] The main active ingredients are organic acids and flavonoids, including catechins, quercetin, vitexin, hyperoside, chlorogenic acid, hawthorn acid, and citric acid.

[0051]

Efficacy

[0052] Cassia seed

[0053] [Nature and flavor] It tastes bitter, sweet and salty, and is slightly cold. It enters the liver, kidney and large intestine meridians.

[0054] [Ingredients] The seeds contain anthraquinone compounds, mainly rhein, rhein methyl ether, rhein phenol, aloe-rhein, as well as blunt-leaved chrysanthemum, cassia bark, cassia bark, aurantium and their glycosides and rhein.

[0055] [Efficacy] It can clear the liver and improve eyesight, promote diuresis and relieve constipation, has a laxative effect, and can lower blood pressure and blood lipids. Cassia anthraquinone glycosides can significantly reduce the high concentration of TLR4 and NF-κB expression caused by a high-fat diet, and can significantly reduce adverse reactions such as skin inflammation and lower blood lipids in NAFLD rats through the action of Cassia anthraquinone glycosides. Cassia anthraquinone glycosides can also inhibit lipid peroxidation and prevent liver cells from being damaged again, so as to achieve the effect of preventing and treating NAFLD. The ethyl acetate extract in Cassia can antagonize lipid peroxidation damage in the liver, protect liver cells, reduce lipids and protect the liver, protect cell membranes, scavenge oxygen free radicals, and inhibit lipid peroxidation.

[0056] Mulberry Leaves

[0057]

Nature and flavor and meridians

[0058]

Ingredients

[0059] [Efficacy] It has the effects of dispersing wind-heat, clearing the lungs and moistening dryness, clearing the liver and improving eyesight. Mulberry leaf alkaloids (MLA) also have many protective effects on the liver, including MLA's protective effect on liver damage caused by D-galactose; MLA has an improvement effect on liver damage induced by a high-fat diet in mice; MLA's main component 1-deoxynojirimycin (DNJ) can improve non-alcoholic fatty liver induced by a high-fat diet.

[0060] Poria

[0061] [Nature and flavor and meridians entered] Sweet, light, neutral in nature, entered the heart, spleen, lung and kidney meridians.

[0062] [Ingredients] The dried sclerotium of the Polyporaceae fungus Poria cocos contains polysaccharides, triterpenes, volatile oils and other chemical components.

[0063] [Efficacy] It has the effects of dispelling dampness and promoting diuresis, benefiting the spleen and stomach and protecting the kidneys, calming the nerves and promoting the production of body fluids. Poria polysaccharide can regulate blood lipid levels and the reverse cholesterol transport process, and improve liver lipid deposition. Poria polysaccharide extract regulates the expression of metabolic enzyme CYP2E1 and inhibits the TLR4 / NF-κB inflammatory signaling pathway, as well as reduces oxidative stress and inflammatory damage. PCP-1C has excellent liver protection activity, can effectively reduce the increase of liver damage characteristic transaminase in serum, increase the activity of liver antioxidant enzymes SOD and GSH-Px, and reduce the production of malondialdehyde and inflammatory factors.

[0064] Atractylodes macrocephala

[0065]

Nature and flavor and meridians

[0066]

Ingredients

[0067] [Effects] Diuresis and swelling, strengthening the exterior and stopping sweating, drying dampness and strengthening the spleen. Atractylodes macrocephala polysaccharide can effectively reduce liver fatty lesions in mice, and can also reduce the liver fat metabolism disorder in laying hens caused by high-fat feed, and can reduce liver damage caused by high-fat diet by regulating the activity of antioxidant enzymes and the expression of related genes in the liver lipid metabolism pathway.

[0068] Astragalus

[0069] [Nature and flavor and meridians] Sweet in taste, slightly warm in nature. Enters the lung, spleen, liver, and kidney meridians.

[0070]

Ingredients

[0071] [Efficacy] It has the effects of replenishing qi and raising yang, replenishing qi and strengthening the exterior, promoting diuresis and reducing swelling, relieving stagnation and relieving arthritis, removing toxins and draining pus, and healing sores and promoting tissue regeneration. Astragalus can protect liver tissue by reducing the expression level of fibrogenic factors. Astragalus total saponin can reduce the degree of peroxidation of enzymes such as superoxide dismutase, allowing liver cells to function normally and reducing the expression of inflammatory factors, thereby effectively reducing the degree of acute liver damage.

[0072] Aged Fuzhuan Tea

[0073] Its main components are tea polyphenols / catechin compounds, theabrownins, tea polysaccharides, alkaloids, microorganisms and their metabolites.

[0074] Among them, tea polyphenols / catechin compounds have been considered to be the main lipid-lowering components of Fuzhuan tea. Catechins also regulate lipid metabolism disorders induced by a high-fat diet, reduce fat accumulation, and reduce the body weight of obese rats by reducing the body fat rate and adipocyte size of rats. Cell experiments have shown that tea polyphenols exert anti-inflammatory effects by inhibiting the expression of Toll-like receptor 4 (TLR4), mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB) signaling pathways in RAW 264.7 macrophages stimulated by lipopolysaccharide, and are dose-dependent. Animal experiments have shown that tea polyphenols can reduce the expression levels of cyclooxygenase-2 (COX-2), interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and plasma monocyte chemoattractant protein-1 (MCP-1), and increase the levels of interleukin-10 (IL-10) and heme oxygenase-1 (HO-1) proteins in model animals, thereby playing an anti-inflammatory role.

[0075] Theabrownin is an important oxidation product of catechins in Fuzhuan tea, which is further oxidized by theaflavins and thearubigins, and has a good lipid-lowering effect. Wang et al.'s research shows that theabrownin can improve intestinal homeostasis, improve lipid and glucose disorders, and reduce the body weight of fed mice by increasing the level of short-chain fatty acids (especially butyric acid). Theabrownin in Pu'er tea can significantly regulate the relevant biochemical indicators in the serum of hyperlipidemia rats, reduce liver fat accumulation, and inhibit the formation of fatty liver. Theabrownin in Sichuan Bian tea can significantly reduce the blood lipid level of hyperlipidemic mice. Both studies show that theabrownin can improve the serum lipid content level of high-fat diet experimental mice. One of the reasons is that it can regulate the key enzymes of lipid metabolism. Other studies have shown that theabrownin can reduce the blood lipid and blood sugar levels and visceral fat coefficient of rats, and has a positive effect on the body's antioxidant response and inflammatory effects; it can also protect liver cells, reduce fatty degeneration and lipid droplet aggregation of liver cells, and reduce liver lipid accumulation.

[0076] Tea polysaccharides can significantly prevent metabolic syndrome in mice induced by a high-fat diet and have a certain effect on lowering blood lipids in rats. Hou Yangfeng et al. used an experimental hyperlipidemia rat model to show that tea polysaccharides can significantly reduce serum total cholesterol in hyperlipidemia rats, enhance anti-atherosclerosis factors, reduce fat deposition in liver cells, and regulate the content of Zn, Cu, and Mg in their livers that are related to lipid metabolism, so that the Zn / Cu ratio tends to a normal level, which has a promoting effect on lowering blood lipids in rats. Tea polysaccharides can reduce lipid peroxidation in the liver, scavenge free radicals, protect liver cell membranes, and maintain normal membrane permeability.

[0077] Alkaloids are mixed reversible inhibitors. Studies have shown that fuzhuan tea alkaloids can effectively reduce fatty liver levels, prevent liver fibrosis and lipid droplet accumulation, and caffeine can inhibit lipid absorption, playing an important role in the lipid-lowering effect of fuzhuan tea.

[0078] Microorganisms and their metabolites play a key role in preventing obesity by regulating intestinal flora. Huang Qun et al. found that the fermented liquid of Eurotium cristatum can improve the pathological conditions such as increased liver cell volume and abnormal accumulation of liver lipids in mice caused by a high-fat diet, promote the digestion and absorption of starch and protein, inhibit fat decomposition and absorption, and have a significant auxiliary lipid-lowering effect.

[0079] The tea beverage for preventing and treating non-alcoholic fatty liver disease provided by the present invention is described in detail below through specific examples.

[0080] Example 1

[0081] A tea for preventing and treating nonalcoholic fatty liver disease comprises the following ingredients by weight: 2.5 parts of cassia seeds, 2.5 parts of mulberry leaves, 1.5 parts of gynostemma pentaphyllum, 1.5 parts of hawthorn, 1.0 part of tangerine peel, 0.5 part of atractylodes macrocephala, 0.5 part of tuckahoe, 1 part of astragalus, and 1 part of aged fu brick tea.

[0082] The preparation process of aged Fuzhuan tea includes:

[0083] Select high-quality dark tea, steam it for 5-7 minutes, pour it into a wooden warehouse, lay it flat at a height of 1m, ferment it for 12 hours, and the fermentation temperature is 50℃;

[0084] Flowering will occur naturally at 25℃ and 65% relative humidity. When white mycelium appears in the brick tea, the temperature will be raised to 28℃ and the humidity will be 80%. When the brick tea is seen to have luxuriant Eurotium cristatum growing, the humidity will be controlled at 55-65% until the flowering is complete.

[0085] After the flowering is completed, the temperature is raised by 3℃ every day until it reaches 50℃ and kept warm for 2 days, then cooled to 35℃ at a rate of 2℃ / day; then heated to 40℃ at a rate of 1℃ / day until the brick tea is dry, and the finished tea is ready;

[0086] The finished tea leaves are fermented and aged in an environment with moderate temperature and humidity, good ventilation, freshness and no odor.

[0087] The preparation method of the tea beverage for preventing and treating non-alcoholic fatty liver disease in this embodiment comprises the following steps:

[0088] Step S1, removing impurities from each raw material, weighing and washing;

[0089] Step S2, performing a primary drying treatment on the washed raw materials;

[0090] Specifically, the washed raw materials are filtered through a water filter device, and the separated raw materials are air-dried at a drying temperature of 60°C;

[0091] Step S3, crushing the raw material after the primary drying, and the particle size of the particles after crushing is 200 mesh;

[0092] Specifically include:

[0093] Step S31, putting the raw material after the primary drying into a pulverizer for primary pulverization;

[0094] Step S32, using a screening device to screen the raw material after the primary crushing, wherein the screening device is a flat circular screen;

[0095] Step S33, performing secondary crushing on the screened large-particle raw materials;

[0096] Step S4, putting the crushed raw materials into a mixer and stirring them evenly;

[0097] Step S5, secondary drying of the mixed raw materials;

[0098] Specifically, the raw materials are placed in a vacuum drying oven for drying, the vacuum degree is 0.05Mpa, and the drying temperature is 60°C;

[0099] Step S6, sterilizing the raw materials after secondary drying;

[0100] Specifically, the raw materials after secondary drying are placed in a sterilization box, and the raw materials are sterilized by ultraviolet lamps. During the sterilization process, the raw materials are turned over by a turning device;

[0101] Step S7, packing the sterilized raw materials into filter bag papers and sealing them.

[0102] Example 2

[0103] A tea drink for preventing and treating nonalcoholic fatty liver disease comprises the following ingredients by weight: 2 parts of cassia seeds, 2 parts of mulberry leaves, 1 part of gynostemma pentaphyllum, 1 part of hawthorn, 0.5 parts of tangerine peel, 1 part of atractylodes macrocephala, 0.8 parts of tuckahoe, 1.5 parts of astragalus, and 1.5 parts of aged fu brick tea.

[0104] The method for preparing the tea beverage for preventing and treating non-alcoholic fatty liver disease in this embodiment is the same as that in Embodiment 1, and will not be described in detail here.

[0105] Example 3

[0106] A tea drink for preventing and treating nonalcoholic fatty liver disease comprises the following ingredients by weight: 4 parts of cassia seeds, 4 parts of mulberry leaves, 2 parts of gynostemma pentaphyllum, 2 parts of hawthorn, 1 part of tangerine peel, 0.6 parts of atractylodes macrocephala, 1 part of tuckahoe, 2 parts of astragalus, and 2 parts of aged fu brick tea.

[0107] The method for preparing the tea beverage for preventing and treating non-alcoholic fatty liver disease in this embodiment is the same as that in Embodiment 1, and will not be described in detail here.

[0108] Example 4

[0109] A tea for preventing and treating nonalcoholic fatty liver disease comprises the following ingredients by weight: 3 parts of cassia seeds, 3 parts of mulberry leaves, 1.2 parts of gynostemma pentaphyllum, 1.5 parts of hawthorn, 1.5 parts of tangerine peel, 0.8 parts of atractylodes macrocephala, 0.5 parts of tuckahoe, 1 part of astragalus, and 1.5 parts of aged fu brick tea.

[0110] The method for preparing the tea beverage for preventing and treating non-alcoholic fatty liver disease in this embodiment is the same as that in Embodiment 1, and will not be described in detail here.

[0111] The tea beverage for preventing and treating non-alcoholic fatty liver disease in Example 1 was subjected to animal experiments to illustrate its effect in preventing non-alcoholic fatty liver disease.

[0112] 1. Preparation of experimental reagents

[0113] Weigh 50g of the tea for preventing and treating non-alcoholic fatty liver disease in Example 1, wrap it tightly with sterile gauze, put it in a sterile beaker, add laboratory grade III water, add 500ml of water and soak for 30min, then put the beaker on the experimental electric furnace for heating, boil it over high heat and then simmer it over low heat for about 30min, filter it after cooling, and set the juice aside; add an appropriate amount of distilled water to the residue (level with the residue) and continue to decoct, cool it after boiling, combine the two liquid medicines and concentrate them to 125ml on low heat, and the concentrated drug concentration is 0.4g / ml. Filter the above liquid medicine with sterile gauze and put it in a sterilized ground-mouth bottle, and store it in a refrigerator at -20℃ for standby use. To prevent the liquid medicine from deteriorating, the concentrated amount of medicine is only used for about 1 week each time. This extract is the extract of the high-dose experimental group, and the extracts of the medium and low-dose experimental groups are diluted 2 times and 4 times respectively.

[0114] 2. Animal Experiment Design and Methods

[0115] SPF C57bl / 6 mice were adaptively raised in a suitable environment (room temperature 23℃-25℃, relative humidity 50%-70%, clean and quiet) for 7 days and then divided into a normal group (10 mice), a model group (20 mice), a low-dose experimental group (10 mice), a medium-dose experimental group (10 mice), a high-dose experimental group (10 mice), and a western medicine group (10 mice) according to a random number table method. Starting from the 8th day, the normal group had free food and water, and the other groups were fed a high-fat diet.

[0116] The high-dose group used 4.1g / kg / d, the medium-dose experimental group used 2.05g / kg / d, and the low-dose experimental group used 1.03g / kg / d; the Western medicine group was gavaged with atorvastatin at a dose of 10mg / kg / d. Before the experiment, the tablets were crushed in a clean mortar and the required volume of saline was added to dissolve them. The normal group and the model group were gavaged with the same dose of saline, and the mice were gavaged at a dose of 10ml / kg / d. The dosage was adjusted weekly according to body weight. The drug was heated in a water bath before use to prevent the stress response caused by the drug being too cold. Gavage began at around 9 am every day and continued for 12 weeks.

[0117] After fasting for 12 hours but not drinking water at the end of the 12th week after gavage, mice in each group were subjected to the following operations:

[0118] (1) After the mice are anesthetized, their eyeballs are removed and blood is collected. After 2 hours of rest, the blood is placed in an EP tube and the serum is separated for testing serum biochemical indicators to avoid repeated freezing and thawing.

[0119] (2) The mice were killed by dislocation, the chest and abdomen of the mice were cut open, and the mice were placed in an ice box or on ice. Fresh liver tissue was collected and stored at -80°C for molecular biology detection. In addition, part of the liver tissue was fixed with 4% paraformaldehyde for histological detection.

[0120] 3. Animal Experiment Results

[0121] 1. The serum transaminase activity of mice in each experimental group was measured. The results are shown in Table 1:

[0122] Table 1: Test results of serum transaminase activity in mice in each experimental group

[0123]

[0124] Note: “*” indicates significant difference compared with the blank group, P < 0.05; “#” indicates significant difference compared with the model group, P < 0.05; “△” indicates significant difference compared with the atorvastatin group, P < 0.05; “▲” indicates significant difference compared with the medium-dose experimental group, P < 0.05.

[0125] Table 1 shows that compared with the blank group, the ALT and AST levels of the model group mice liver increased (P<0.05); compared with the model group, the ALT and AST levels of the high, medium, and low dose groups of the tea drink of the present invention and the atorvastatin group decreased (P<0.05), among which the ALT level of the medium dose group was the lowest (P<0.05); the AST level of the atorvastatin group was lower than that of the medium dose group (P<0.05), there was no significant difference in AST levels between the medium and low dose groups (P>0.05), and the AST level of the high dose group was lower than that of the medium dose group (P<0.05). This shows that the tea drink of the present invention improves the liver function level of NAFLD to a certain extent.

[0126] 2. Determination of TC, LDL-c, HDL-c, and TC / HDL levels in the serum of mice in each experimental group. The results are shown in Table 2:

[0127] Table 2: Results of determination of TC, LDL-c, HDL-c, and TC / HDL levels in the serum of mice in each experimental group

[0128]

[0129] Note: Compared with the model group, *<0.05; **<0.01.

[0130] Table 2 shows that in the comparison of blood lipids, compared with the blank control group, the total cholesterol (TC), LDL, and high-density lipoprotein (HDL) levels in the serum of the model group mice increased (P < 0.05). The TC and LDL-c levels in the atorvastatin group and the different dose groups of the tea drink of the present invention decreased (P < 0.05); compared with atorvastatin, the TC and LDL-c levels in the high and medium dose groups of the tea drink of the present invention increased, and the HDL content decreased (P < 0.05). This shows that the tea drink of the present invention improves the lipid metabolism disorder of NAFLD mice to a certain extent.

[0131] 3. Determination of oxidative stress indicators

[0132] The liver tissue was taken out of the low-temperature refrigerator, rinsed with ice saline, and then cut into pieces with sterilized ophthalmic scissors and added with saline in a ratio of m (liver tissue): V (saline) = 1g: 9mL (operated on ice throughout the process), homogenized with an automatic homogenizer (interval every 3s to prevent excessive heat generation) to make a 10% liver homogenate, centrifuged at 1000g (4°C) for 15min, removed the supernatant, added with an appropriate amount of saline to dilute to a suitable concentration range for the determination of SOD, GSH-PX activity and MDA mass molar concentration in liver tissue. The results are shown in Table 3:

[0133] Table 3: SOD, GSH-Px activity and MDA mass molar concentration in liver tissue of mice in each experimental group

[0134]

[0135] Note: “*” indicates significant difference compared with the blank group, P < 0.05; “#” indicates significant difference compared with the model group, P < 0.05; “△” indicates significant difference compared with the atorvastatin group, P < 0.05; “▲” indicates significant difference compared with the medium-dose experimental group, P < 0.05.

[0136] Table 3 shows that compared with the blank group, the activities of SOD and GSH-Px in the liver of mice in the model group decreased, and the content of MDA increased (P<0.05); compared with the model group, the activities of SOD and GSH-Px in the high, medium and low dose experimental groups increased, and the content of MDA decreased (P<0.05); compared with the atorvastatin group, the activity of SOD in the high dose group increased (P<0.05), and the activity of GSH-Px in the low dose group was slightly lower (P<0.05), and there were no significant differences in the other indicators between the dose groups and the statin group (P>0.05); compared with the medium dose group, the activities of SOD and GSH-Px in the low dose group were slightly lower, and the content of MDA was slightly higher (P<0.05), and the activity of SOD in the high dose group increased (P<0.05), and there were no significant differences in GSH-Px activity and MDA content (P>0.05).

[0137] Oxidative damage to liver cells is one of the important factors that induce NAFLD. The level of SOD activity indirectly reflects the body's ability to scavenge oxygen free radicals. Excessive MDA has potential cytotoxicity and is an important indicator for evaluating the degree of cell damage. GSH-Px can maintain the integrity of the cell membrane structure. Therefore, the body's antioxidant status can be inferred by detecting these three indicators: SOD, MDA and GSH-Px. The above test data show that the activities of SOD and GSH-Px in the liver of mice in the model group are reduced, and the MDA content is increased, reflecting that oxidative damage does exist in NAFLD model mice; preventive administration of different dosage groups of the present invention can increase the activity of SOD and GSH-Px in the liver, reduce the MDA content and the activities of ALT and AST, indicating that the tea of ​​the present invention can play an antioxidant role, thereby reducing oxidative damage to liver cells.

[0138] In summary, the tea for preventing and treating non-alcoholic fatty liver disease of the present invention can significantly inhibit weight gain, adipose tissue accumulation, adipocyte proliferation, liver weight, liver lipid deposition induced by a high-fat diet, and improve liver function levels, reduce serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels, and play an antioxidant role, thereby reducing oxidative damage to liver cells, so as to achieve a good effect of preventing non-alcoholic fatty liver disease.

[0139] The embodiments of the present invention are described in detail above, but the present invention is not limited to the described embodiments. For those skilled in the art, various changes, modifications, substitutions and variations made to these embodiments without departing from the principles and spirit of the present invention are still within the protection scope of the present invention.

Claims

1. A tea drink for preventing and treating non-alcoholic fatty liver disease, characterized in that: The invention is composed of the following ingredients by weight: 2-4 parts of cassia seeds, 2-4 parts of mulberry leaves, 1-2 parts of gynostemma pentaphyllum, 1-2 parts of hawthorn, 0.5-1.5 parts of tangerine peel, 0.5-1 part of atractylodes macrocephala, 0.5-1 part of poria, 1-2 parts of astragalus, and 1-2 parts of aged fu brick tea.

2. The tea drink for preventing and treating non-alcoholic fatty liver disease according to claim 1, characterized in that: The following components are calculated by weight Composition: 2.5 parts of Cassia seeds, 2.5 parts of mulberry leaves, 1.5 parts of Gynostemma pentaphyllum, 1.5 parts of hawthorn, 1.0 part of dried tangerine peel, 0.5 part of Atractylodes macrocephala, 0.5 part of Poria cocos, 1 part of Astragalus, and 1 part of aged Fu brick tea.

3. The tea drink for preventing and treating non-alcoholic fatty liver disease according to claim 1 or 2, characterized in that: The aged Fuzhuan tea is prepared by the following preparation process: Select high-quality dark tea, steam it for 5-7 minutes, pour it into wooden warehouse, lay it flat at a height of 1-1.2m, ferment it for 12-15 hours, and the fermentation temperature is 40-60℃; Flowering will occur naturally at 24-26℃ and relative humidity of 65-75%. When white mycelium appears in the brick tea, the temperature will be raised to 27.5-28.5℃ and the humidity will be 75%-85%. When the brick tea is seen to have lush Eurotium cristatum growing, the humidity will be controlled at 55-65% until the flowering is complete. After the flowering is completed, the temperature is raised by 3-4℃ every day until it reaches 50℃ and kept warm for 2 days, then cooled down to 35℃ at a rate of 2℃ / day; then heated up to 40℃ at a rate of 1℃ / day until the brick tea is dry, and the finished tea is ready; The finished tea leaves are fermented and aged in an environment with moderate temperature and humidity, good ventilation, freshness and no odor.

4. A method for preparing a tea drink for preventing and treating non-alcoholic fatty liver disease as claimed in claim 1 or 2, characterized in that: The steps include: Step S1, removing impurities from each raw material, weighing and washing; Step S2, performing a primary drying treatment on the washed raw materials; Step S3, crushing the raw material after the primary drying, and the particle size of the particles after crushing is 150-200 mesh; Step S4, putting the crushed raw materials into a mixer and stirring them evenly; Step S5, secondary drying of the mixed raw materials; Step S6, sterilizing the raw materials after secondary drying; Step S7, packing the sterilized raw materials into filter bag papers and sealing them.

5. The method for preparing a tea drink for preventing and treating non-alcoholic fatty liver disease according to claim 4, characterized in that: In step S2, the initial drying temperature is 60-80°C.

6. The method for preparing a tea drink for preventing and treating non-alcoholic fatty liver disease according to claim 4, characterized in that: The step S3 specifically includes: Step S31, putting the raw material after the primary drying into a pulverizer for primary pulverization; Step S32, using a screening device to screen the raw material after the primary crushing, wherein the screening device is a flat circular screen; Step S33, secondary crushing of the screened large-particle raw materials.

7. The method for preparing a tea drink for preventing and treating non-alcoholic fatty liver disease according to claim 4, characterized in that: In step S5, the raw material is placed in a vacuum drying oven for drying, the vacuum degree is 0.01-0.1Mpa, and the drying temperature is 60-80°C.

8. The method for preparing a tea drink for preventing and treating non-alcoholic fatty liver disease according to claim 4, characterized in that: In step S6, the raw material is sterilized by ultraviolet light.

Images